MUNICH, Germany and NEW YORK, June 9 /PRNewswire/ -- Xerion Pharmaceuticals AG and Stemline Therapeutics, Inc. have entered into a collaborative agreement under which the two privately-held companies plan to identify novel protein targets expressed on cancer stem cells. Under the terms of the agreement, Xerion will apply its Xstream(R) technology to Stemline's proprietary cancer stem cell platform (StemScreen(TM)) to identify novel and druggable oncology targets. The companies will share equally and have the option to co-develop any targets arising from this collaboration.
Xerion's Xstream(R) technology has been applied to human cancer cells and has successfully generated a number of cancer-relevant targets. This has led to the development of fully human antibody therapeutics against some of these targets. Stemline, together with its collaborator Dr. Malcolm Moore of the Memorial Sloan-Kettering Cancer Center, who previously led the team that discovered human G-CSF (later, Neupogen(R)), have built a proprietary and comprehensive cancer stem cell platform. Cancer stem cells are a highly virulent subpopulation of tumors important in the development and persistence of malignancy.
"We are excited about applying our Xstream(R) technology to Stemline's platform," said Markus Ewert, Ph.D., President and CEO of Xerion. "We believe that screening against cancer stem cells will enable us to find new, druggable targets for cancer. We look forward to working with Stemline, a leader of this rapidly emerging cancer stem cell space."
"Stemline is especially pleased to have integrated its cancer stem cell platform with Xerion's robust and validated Xstream(R) technology," explained Ivan Bergstein, M.D, CEO of Stemline. "We expect that this landmark collaboration will lead to the identification of important oncology targets and the development of the first pipeline of drug candidates that target cancer stem cells."
About Xerion Pharmaceuticals
Xerion Pharmaceuticals is building a pipeline of novel therapeutic targets and antibodies in the indications of cancer and immunological disorders. To identify targets, Xerion solely focuses on proteins, using proprietary Xstream(R) technology to selectively block their function in diseased cells thereby mimicking the activity of a drug. Xerion integrates this approach with the ability to rapidly generate therapeutic antibody leads. Xerion is applying its technologies and developing these targets and antibodies independently and in conjunction with its partners. For additional information, please visit Xerion's Website at http://www.xerion-pharma.com/.
Xerion is headquartered in Munich, Germany and its subsidiary Xerion Pharmaceuticals Inc. is based in Cambridge, MA, U.S.A. The Company has license and collaborative agreements with Arius Research Inc., Cambridge Antibody Technology Ltd., Medarex Inc., Xoma Ltd. and several research institutes.
Stemline Therapeutics, Inc. is a biotechnology company dedicated to the discovery, acquisition, and development of novel oncology compounds that target "cancer stem cells". The field of cancer stem cells represents a rapidly emerging and exciting new area of cancer biology and oncology. Stemline has built a proprietary discovery platform (StemScreen(TM)) that enables the identification of new targets and lead candidates that attack cancer stem cells. Stemline is also acquiring compounds within its area of expertise. Stemline plans to advance a pipeline of drug candidates through pre-clinical animal testing and into human clinical trials. For additional information, please visit Stemline's Website at http://www.stemline.com/.
Stemline is headquartered in New York, New York, U.S.A.
Stemline Therapeutics, Inc.
CONTACT: Ivan Bergstein of Stemline Therapeutics, Inc., +1-212-831-1111,Fax: +1-212-244-0161, email@example.com; or Markus Ewert of XerionPharmaceuticals AG, +49-89-86-307-0, Fax: +49-89-86-307-112,firstname.lastname@example.org; or Yukari Perrella of Xerion Pharmaceuticals Inc.,+1-617-621-7123, Fax: +1-617-621-7124, email@example.com